Cellular Therapies Show Sustained Promise in Hematologic Malignancies, but Access Remains Uneven

Cellular therapies like chimeric antigen receptor (CAR) T-cell therapy and tumor-infiltrating lymphocyte therapy have revolutionized cancer treatment, showing remarkable responses in patients with B-cell malignancies and multiple myeloma. Despite their success, equitable access remains a significant challenge, influenced by multiple factors including logistical and financial burdens, institutional and regulatory protocols, disparities in referral and awareness, and racial and socioeconomic inequities. Efforts at national and international levels are attempting to promote equity in access to cellular therapies.